A new biomaterial for the control of infection in the burn wound.
A synthetic dressing has been developed that isolates the burn wound to protect patients from microbial contamination. This dressing is unique as it is formed from a 2-component system directly on the wound, leaving no voids for microbial proliferation. The synthetic cover, HYDRON Burn Dressing, adheres to the entire wound surface so that additional dressings are not required. It is sufficiently flexible to permit patient mobility. The components used to form the dressing are an ultra-pure, high molecular weight form of HYDRON, a hydrophilic polymer, poly (2-hydroxyethyl methacrylate) and Polethylene Glycol-400. The dressing is intended to be applied directly to the wound immediately post-burn, prior to sloughing or removal of the eschar, a period in the burn therapy regimen for which satisfactory alternative dressings are not readily available. Decreased frequency of dressing changes compared to conventional procedure provides an additional benefit with a corresponding reduction in pain to the patient. Gross examination of the wounds under the dressing has shown that the healing process proceeds similarly to that of wounds under conventional treatment. There is no evidence of fluid accumulation or maceration or desiccation of the eschar. In our series of 32 patients the barrier dressing formed on the wound has offered a new, effective procedure for treatment of the burn wound.
D000180:Acrylic Resins / Q000627:therapeutic use*; D000287:Administration, Topical; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001419:Bacteria / Q000187:drug effects / Q000254:growth & development; D001424:Bacterial Infections / Q000473:pathology / Q000517:prevention & control*; D001458:Bandages; D001672:Biocompatible Materials; D002056:Burns / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D004058:Diffusion; D004927:Escherichia coli Infections / Q000517:prevention & control; D006801:Humans; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011109:Polymethacrylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014946:Wound Infection / Q000209:etiology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*
D000180:Acrylic Resins; D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D011109:Polymethacrylic Acids; D011092:Polyethylene Glycols